Nanovi, a Lyngby, Denmark-based developer of products based on advanced biomaterials for use in the treatment of cancer, secured €600k in funding.
Backers included SEED Capital, which invested earlier this year and Vækstfonden, which just joined in a second closing.
The company intends to use the funds to bring BioXmark™ to a proof-of-concept.
Led by Morten Albrechtsen, CEO and co-founder, Nanovi is developing BioXmark, an injectable tissue liquid marker, used to improve accuracy in the radiation treatment of patients with cancer.
It will be available for commercial use in Europe around 2015.
FinSMEs
02/12/2013